Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis
CONCLUSIONS: The comparative effects of different ESAs on blood transfusions, death (any cause and cardiovascular), major cardiovascular events, myocardial infarction, stroke, vascular access thrombosis, kidney failure, fatigue and breathlessness were uncertain.PMID:36791280 | PMC:PMC9924302 | DOI:10.1002/14651858.CD010590.pub3 (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - February 15, 2023 Category: General Medicine Authors: Edmund Ym Chung Suetonia C Palmer Valeria M Saglimbene Jonathan C Craig Marcello Tonelli Giovanni Fm Strippoli Source Type: research
Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis
CONCLUSIONS: The comparative effects of different ESAs on blood transfusions, death (any cause and cardiovascular), major cardiovascular events, myocardial infarction, stroke, vascular access thrombosis, kidney failure, fatigue and breathlessness were uncertain.PMID:36791280 | DOI:10.1002/14651858.CD010590.pub3 (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - February 15, 2023 Category: General Medicine Authors: Edmund Ym Chung Suetonia C Palmer Valeria M Saglimbene Jonathan C Craig Marcello Tonelli Giovanni Fm Strippoli Source Type: research
Pharmacist-driven epoetin alfa-epbx dosing for hospitalized patients
CONCLUSION: Pharmacist-driven ESA dosing was associated with significant decreases in ESA average acquisition cost and average total dose per patient.PMID:36680797 | DOI:10.1093/ajhp/zxad004 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - January 21, 2023 Category: Drugs & Pharmacology Authors: Eric Linn Heather Morrison Michael Sanchez Theodore Heierman Source Type: research
Pharmacist-driven epoetin alfa-epbx dosing for hospitalized patients
CONCLUSION: Pharmacist-driven ESA dosing was associated with significant decreases in ESA average acquisition cost and average total dose per patient.PMID:36680797 | DOI:10.1093/ajhp/zxad004 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - January 21, 2023 Category: Drugs & Pharmacology Authors: Eric Linn Heather Morrison Michael Sanchez Theodore Heierman Source Type: research
Biosimilar erythropoietin in anemia treatment (BEAT)—Efficacy and safety of a 1:1 dose conversion from EPREX® to EPIAO® in patients with end-stage renal disease on hemodialysis: A prospective, randomized, double blind, parallel group study
Conclusion:
EPIAO® demonstrated promising effectiveness and manageable safety in patients with end-stage renal disease on hemodialysis. (Source: Medicine)
Source: Medicine - November 25, 2022 Category: Internal Medicine Tags: Research Article: Clinical Trial/Experimental Study Source Type: research
Epo and the athlete biological passport: hematological results from a placebo ‐controlled, boosting and microdose epo administration in male recreational athletes
AbstractHematological results in the context of the Athlete Biological Passport (ABP) from a placebo-controlled EPO administration study are provided here. Twelve participants administered eight subcutaneous boosting doses of epoetin alfa (at 40 IU/kg) over the course of twenty days. After a ten-day washout period, the same volunteers administered six microdoses (900 IU), intravenously, over thirteen days. A blinded Placebo cohort followed the same dosing pattern, administering saline instead of EPO. All participants supplemented with oral iron, daily, throughout the entirety of the study. In the EPO cohort, as expected, s...
Source: Drug Testing and Analysis - September 17, 2022 Category: Drugs & Pharmacology Authors: Geoffrey D. Miller,
Jacob Husk,
Andre K. Crouch,
Daniel Eichner Tags: RESEARCH ARTICLE Source Type: research
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial
CONCLUSIONS: Daprodustat was noninferior to epoetin in hemoglobin response and was generally well tolerated.CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Anemia Studies in Chronic Kidney Disease: Erythropoiesis via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Three Times Weekly Dosing in Dialysis (ASCEND-TD), NCT03400033.PMID:35918106 | DOI:10.2215/CJN.00550122 (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - August 2, 2022 Category: Urology & Nephrology Authors: Daniel W Coyne Ajay K Singh Renato D Lopes Christine K Bailey Tara L DiMino Chun Huang Jeffrey Connaire Anjay Rastogi Sung-Gyun Kim Marcelo Orias Sapna Shah Vickas Patel Alexander R Cobitz Christoph Wanner Source Type: research
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial
CONCLUSIONS: Daprodustat was noninferior to epoetin in hemoglobin response and was generally well tolerated.CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Anemia Studies in Chronic Kidney Disease: Erythropoiesis via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Three Times Weekly Dosing in Dialysis (ASCEND-TD), NCT03400033.PMID:35918106 | DOI:10.2215/CJN.00550122 (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - August 2, 2022 Category: Urology & Nephrology Authors: Daniel W Coyne Ajay K Singh Renato D Lopes Christine K Bailey Tara L DiMino Chun Huang Jeffrey Connaire Anjay Rastogi Sung-Gyun Kim Marcelo Orias Sapna Shah Vickas Patel Alexander R Cobitz Christoph Wanner Source Type: research
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial
CONCLUSIONS: Daprodustat was noninferior to epoetin in hemoglobin response and was generally well tolerated.CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Anemia Studies in Chronic Kidney Disease: Erythropoiesis via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Three Times Weekly Dosing in Dialysis (ASCEND-TD), NCT03400033.PMID:35918106 | DOI:10.2215/CJN.00550122 (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - August 2, 2022 Category: Urology & Nephrology Authors: Daniel W Coyne Ajay K Singh Renato D Lopes Christine K Bailey Tara L DiMino Chun Huang Jeffrey Connaire Anjay Rastogi Sung-Gyun Kim Marcelo Orias Sapna Shah Vickas Patel Alexander R Cobitz Christoph Wanner Source Type: research
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial
CONCLUSIONS: Daprodustat was noninferior to epoetin in hemoglobin response and was generally well tolerated.CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Anemia Studies in Chronic Kidney Disease: Erythropoiesis via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Three Times Weekly Dosing in Dialysis (ASCEND-TD), NCT03400033.PMID:35918106 | DOI:10.2215/CJN.00550122 (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - August 2, 2022 Category: Urology & Nephrology Authors: Daniel W Coyne Ajay K Singh Renato D Lopes Christine K Bailey Tara L DiMino Chun Huang Jeffrey Connaire Anjay Rastogi Sung-Gyun Kim Marcelo Orias Sapna Shah Vickas Patel Alexander R Cobitz Christoph Wanner Source Type: research
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial
CONCLUSIONS: Daprodustat was noninferior to epoetin in hemoglobin response and was generally well tolerated.CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Anemia Studies in Chronic Kidney Disease: Erythropoiesis via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Three Times Weekly Dosing in Dialysis (ASCEND-TD), NCT03400033.PMID:35918106 | DOI:10.2215/CJN.00550122 (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - August 2, 2022 Category: Urology & Nephrology Authors: Daniel W Coyne Ajay K Singh Renato D Lopes Christine K Bailey Tara L DiMino Chun Huang Jeffrey Connaire Anjay Rastogi Sung-Gyun Kim Marcelo Orias Sapna Shah Vickas Patel Alexander R Cobitz Christoph Wanner Source Type: research
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial
CONCLUSIONS: Daprodustat was noninferior to epoetin in hemoglobin response and was generally well tolerated.CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Anemia Studies in Chronic Kidney Disease: Erythropoiesis via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Three Times Weekly Dosing in Dialysis (ASCEND-TD), NCT03400033.PMID:35918106 | DOI:10.2215/CJN.00550122 (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - August 2, 2022 Category: Urology & Nephrology Authors: Daniel W Coyne Ajay K Singh Renato D Lopes Christine K Bailey Tara L DiMino Chun Huang Jeffrey Connaire Anjay Rastogi Sung-Gyun Kim Marcelo Orias Sapna Shah Vickas Patel Alexander R Cobitz Christoph Wanner Source Type: research
Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D)
CONCLUSION: In this study, desidustat was found to be noninferior to epoetin in the treatment of anemia in CKD patients on dialysis and it was well-tolerated. Clinical Trial Registry Identifier: CTRI/2019/12/022312 (India).PMID:35462369 | DOI:10.1159/000523949 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - April 24, 2022 Category: Urology & Nephrology Authors: Sishir Gang Prakash Khetan Deepak Varade Venkata Ramakrishna Chinta Siddharth Mavani Umesh Gupta S Venkata Krishna Reddy Sunil Rajanna Tarun Jeloka Vivek Ruhela Kevinkumar Kansagra Pooja Kanani Jayesh Bhatt Kuldipsinh Zala Study Investigator Group Source Type: research
Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D)
CONCLUSION: In this study, desidustat was found to be noninferior to epoetin in the treatment of anemia in CKD patients on dialysis and it was well-tolerated. Clinical Trial Registry Identifier: CTRI/2019/12/022312 (India).PMID:35462369 | DOI:10.1159/000523949 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - April 24, 2022 Category: Urology & Nephrology Authors: Sishir Gang Prakash Khetan Deepak Varade Venkata Ramakrishna Chinta Siddharth Mavani Umesh Gupta S Venkata Krishna Reddy Sunil Rajanna Tarun Jeloka Vivek Ruhela Kevinkumar Kansagra Pooja Kanani Jayesh Bhatt Kuldipsinh Zala Study Investigator Group Source Type: research
